Amicus CPO equity cashed out in BioMarin merger

Amicus Therapeutics’ Chief People Officer David Michael Clark disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Amicus Therapeutics’ Chief People Officer David Michael Clark disposed of his equity in connection with the company’s acquisition by BioMarin Pharmaceutical. The filing shows 221,811 shares of Common Stock were surrendered at $14.50 per share, including 130,942 shares and 90,869 restricted stock units that vested at closing.

Multiple fully vested stock option grants covering tens of thousands of shares each were cancelled and converted into cash. For each option, Clark became entitled to a cash payment equal to the excess of $14.50 over the option’s exercise price, multiplied by the shares subject to that option. Following these transactions, the Form 4 reports zero remaining direct holdings.

Insights

All of the CPO’s Amicus equity was cashed out at merger close.

The Form 4 shows David Michael Clark, Chief People Officer of Amicus Therapeutics, disposing of Common Stock, restricted stock units, and multiple fully vested stock option grants when BioMarin’s acquisition of Amicus was consummated at $14.50 per share.

Rather than open‑market trading, these are mechanical merger-related transactions: shares and options were surrendered to the issuer and converted into cash consideration based on the $14.50 deal price and each option’s exercise price. The filing reports zero remaining direct holdings, consistent with a full equity cash-out at closing.

Insider Trade Summary

Disposition: 897,531 shares

Disposition 8 txns

Insider Clark David Michael

Role Chief People Officer

Type	Security	Shares	Price	Value
Disposition	Stock Options (right to buy)	84,842	$0.00	$0.00
Disposition	Stock Options (right to buy)	77,134	$0.00	$0.00
Disposition	Stock Options (right to buy)	91,439	$0.00	$0.00
Disposition	Stock Options (right to buy)	108,266	$0.00	$0.00
Disposition	Stock Options (right to buy)	105,388	$0.00	$0.00
Disposition	Stock Options (right to buy)	83,221	$0.00	$0.00
Disposition	Stock Options (right to buy)	125,430	$0.00	$0.00
Disposition	Common Stock	221,811	$14.50	$3.22M

Holdings After Transaction: Stock Options (right to buy) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (4)

F1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 130,942 shares of Common Stock and 90,869 restricted stock units (which vested in full in connection with consummation of the Merger).
F2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
F3. Each Option was fully vested.
F4. Each Option vested in full in connection with consummation of the Merger.

Key Figures

Common Stock disposed: 221,811 shares at $14.50 Common shares component: 130,942 shares Restricted stock units vested: 90,869 RSUs +5 more

8 metrics

Common Stock disposed 221,811 shares at $14.50 Surrendered in connection with BioMarin merger

Common shares component 130,942 shares Part of 221,811 shares surrendered at merger close

Restricted stock units vested 90,869 RSUs Vested in full upon consummation of the merger

Option grant size 125,430 options at $9.41 Fully vested option cancelled for cash based on $14.50 price

Option grant size 83,221 options at $14.24 Fully vested option cancelled and paid in cash at closing

Option grant size 105,388 options at $11.93 Fully vested option cancelled for cash at merger

Option grant size 108,266 options at $12.11 Fully vested option cancelled for cash at merger

Option grant size 91,439 options at $9.55 Fully vested option cancelled for cash at merger

Key Terms

restricted stock units, Merger, stock option, exercise price, +1 more

5 terms

restricted stock units financial

"which included 130,942 shares of Common Stock and 90,869 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Merger financial

"disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger")"

A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.

stock option financial

"each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

fully vested financial

"Each Option was fully vested."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amicus Therapeutics (FOLD) report in this Form 4 for David Michael Clark?

The Form 4 reports that Chief People Officer David Michael Clark disposed of all reported Amicus equity in connection with BioMarin’s acquisition, surrendering Common Stock, restricted stock units, and vested stock options for cash tied to the $14.50-per-share merger price.

How many Amicus Therapeutics shares were disposed of in the merger for FOLD’s CPO?

Clark disposed of 221,811 shares of Common Stock at $14.50 per share, including 130,942 shares and 90,869 restricted stock units that vested at consummation of the merger with BioMarin, according to the Form 4 footnotes describing the transaction structure.

What happened to David Michael Clark’s Amicus stock options in the BioMarin merger?

Each reported Amicus stock option was cancelled at closing and converted into a cash payment. The payment equals the excess of the $14.50 merger price over the option’s exercise price, multiplied by the number of shares subject to that option, with each option fully vested at consummation.

Were David Michael Clark’s transactions in FOLD shares open-market sales?

No, the Form 4 describes issuer dispositions tied to the merger. Shares and options were surrendered in connection with consummation of BioMarin’s acquisition of Amicus, receiving cash consideration based on the $14.50 deal price rather than through open-market buying or selling.

Does David Michael Clark retain any Amicus Therapeutics holdings after the BioMarin deal?

The Form 4 reports zero shares and options remaining after the merger-related dispositions. Common Stock, restricted stock units, and multiple fully vested option grants were cancelled or surrendered and converted into cash as part of BioMarin’s acquisition of Amicus Therapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/27/2026 - 04:38 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clark David Michael

(Last)

(First)

(Middle)

47 HULFISH STREET

(Street)

PRINCETON

NEW JERSEY

08542

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief People Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/27/2026		D		221,811⁽¹⁾	D	$14.5	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (right to buy)	$12.84	04/27/2026		D⁽²⁾			84,842	⁽³⁾	10/09/2028	Common Stock	84,842	⁽²⁾	0	D
Stock Options (right to buy)	$10.04	04/27/2026		D⁽²⁾			77,134	⁽³⁾	01/02/2029	Common Stock	77,134	⁽²⁾	0	D
Stock Options (right to buy)	$9.55	04/27/2026		D⁽²⁾			91,439	⁽³⁾	01/02/2030	Common Stock	91,439	⁽²⁾	0	D
Stock Options (right to buy)	$12.11	04/27/2026		D⁽²⁾			108,266	⁽³⁾	01/14/2032	Common Stock	108,266	⁽²⁾	0	D
Stock Options (right to buy)	$11.93	04/27/2026		D⁽²⁾			105,388	⁽⁴⁾	01/03/2033	Common Stock	105,388	⁽²⁾	0	D
Stock Options (right to buy)	$14.24	04/27/2026		D⁽²⁾			83,221	⁽⁴⁾	01/02/2034	Common Stock	83,221	⁽²⁾	0	D
Stock Options (right to buy)	$9.41	04/27/2026		D⁽²⁾			125,430	⁽⁴⁾	01/03/2035	Common Stock	125,430	⁽²⁾	0	D

Explanation of Responses:

1. The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 130,942 shares of Common Stock and 90,869 restricted stock units (which vested in full in connection with consummation of the Merger).

2. In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

3. Each Option was fully vested.

4. Each Option vested in full in connection with consummation of the Merger.

	/s/ Christian Formica, Attorney-in-Fact	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Amicus CPO equity cashed out in BioMarin merger

Rhea-AI Filing Summary